Biotech Retrophin files for a $40 million IPO

Shutterstock photo

Retrophin, which is developing treatments for postpartum milk let-down, Schizophrenia and Autism, filed on Wednesday with the SEC to raise up to $40 million in an initial public offering. The New York, NY-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol RTRX. The company is currently traded on the OTCQB under the same ticker. Bookrunners and pricing terms were not disclosed in the preliminary prospectus.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by